Toward cell therapy using placenta-derived cells: Disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table

Ornella Parolini, Francesco Alviano, Irene Bergwerf, Diana Boraschi, Cosimo De Bari, Peter De Waele, Massimo Dominici, Marco Evangelista, Werner Falk, Simone Hennerbichler, David C Hess, Giacomo Lanzoni, Bing Liu, Fabio Marongiu, Colin McGuckin, Stefan Mohr, Maria Luisa Nolli, Racheli Ofir, Peter Ponsaerts, Luca RomagnoliAbraham Solomon, Maddalena Soncini, Stephen Strom, Daniel Surbek, Sankar Venkatachalam, Susanne Wolbank, Steffen Zeisberger, Andy Zeitlin, Andreas Zisch, Cesar V. Borlongan

Research output: Contribution to journalReview article

105 Citations (Scopus)

Abstract

Among the many cell types that may prove useful to regenerative medicine, mounting evidence suggests that human term placenta-derived cells will join the list of significant contributors. In making new cell therapy-based strategies a clinical reality, it is fundamental that no a priori claims are made regarding which cell source is preferable for a particular therapeutic application. Rather, ongoing comparisons of the potentiality and characteristics of cells from different sources should be made to promote constant improvement in cell therapies, and such comparisons will likely show that individually tailored cells can address disease-specific clinical needs. The principle underlying such an approach is resistance to the notion that comprehensive characterization of any cell type has been achieved, neither in terms of phenotype nor risks-to-benefits ratio. Tailoring cell therapy approaches to specific conditions also requires an understanding of basic disease mechanisms and close collaboration between translational researchers and clinicians, to identify current needs and shortcomings in existing treatments. To this end, the international workshop entitled "Placenta-derived stem cells for treatment of inflammatory diseases: moving toward clinical application" was held in Brescia, Italy, in March 2009, and aimed to harness an understanding of basic inflammatory mechanisms inherent in human diseases with updated findings regarding biological and therapeutic properties of human placenta-derived cells, with particular emphasis on their potential for treating inflammatory diseases. Finally, steps required to allow their future clinical application according to regulatory aspects including good manufacturing practice (GMP) were also considered. In September 2009, the International Placenta Stem Cell Society (IPLASS) was founded to help strengthen the research network in this field.

Original languageEnglish (US)
Pages (from-to)143-154
Number of pages12
JournalStem Cells and Development
Volume19
Issue number2
DOIs
StatePublished - Feb 1 2010

Fingerprint

Cell- and Tissue-Based Therapy
Placenta
Cell Biology
Stem Cells
Regenerative Medicine
Therapeutics
Italy
Research Personnel
Phenotype
Education
Research

ASJC Scopus subject areas

  • Hematology
  • Developmental Biology
  • Cell Biology

Cite this

Toward cell therapy using placenta-derived cells : Disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. / Parolini, Ornella; Alviano, Francesco; Bergwerf, Irene; Boraschi, Diana; De Bari, Cosimo; De Waele, Peter; Dominici, Massimo; Evangelista, Marco; Falk, Werner; Hennerbichler, Simone; Hess, David C; Lanzoni, Giacomo; Liu, Bing; Marongiu, Fabio; McGuckin, Colin; Mohr, Stefan; Nolli, Maria Luisa; Ofir, Racheli; Ponsaerts, Peter; Romagnoli, Luca; Solomon, Abraham; Soncini, Maddalena; Strom, Stephen; Surbek, Daniel; Venkatachalam, Sankar; Wolbank, Susanne; Zeisberger, Steffen; Zeitlin, Andy; Zisch, Andreas; Borlongan, Cesar V.

In: Stem Cells and Development, Vol. 19, No. 2, 01.02.2010, p. 143-154.

Research output: Contribution to journalReview article

Parolini, O, Alviano, F, Bergwerf, I, Boraschi, D, De Bari, C, De Waele, P, Dominici, M, Evangelista, M, Falk, W, Hennerbichler, S, Hess, DC, Lanzoni, G, Liu, B, Marongiu, F, McGuckin, C, Mohr, S, Nolli, ML, Ofir, R, Ponsaerts, P, Romagnoli, L, Solomon, A, Soncini, M, Strom, S, Surbek, D, Venkatachalam, S, Wolbank, S, Zeisberger, S, Zeitlin, A, Zisch, A & Borlongan, CV 2010, 'Toward cell therapy using placenta-derived cells: Disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table', Stem Cells and Development, vol. 19, no. 2, pp. 143-154. https://doi.org/10.1089/scd.2009.0404
Parolini, Ornella ; Alviano, Francesco ; Bergwerf, Irene ; Boraschi, Diana ; De Bari, Cosimo ; De Waele, Peter ; Dominici, Massimo ; Evangelista, Marco ; Falk, Werner ; Hennerbichler, Simone ; Hess, David C ; Lanzoni, Giacomo ; Liu, Bing ; Marongiu, Fabio ; McGuckin, Colin ; Mohr, Stefan ; Nolli, Maria Luisa ; Ofir, Racheli ; Ponsaerts, Peter ; Romagnoli, Luca ; Solomon, Abraham ; Soncini, Maddalena ; Strom, Stephen ; Surbek, Daniel ; Venkatachalam, Sankar ; Wolbank, Susanne ; Zeisberger, Steffen ; Zeitlin, Andy ; Zisch, Andreas ; Borlongan, Cesar V. / Toward cell therapy using placenta-derived cells : Disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. In: Stem Cells and Development. 2010 ; Vol. 19, No. 2. pp. 143-154.
@article{b8ce863e27144b81acc82cac024c6203,
title = "Toward cell therapy using placenta-derived cells: Disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table",
abstract = "Among the many cell types that may prove useful to regenerative medicine, mounting evidence suggests that human term placenta-derived cells will join the list of significant contributors. In making new cell therapy-based strategies a clinical reality, it is fundamental that no a priori claims are made regarding which cell source is preferable for a particular therapeutic application. Rather, ongoing comparisons of the potentiality and characteristics of cells from different sources should be made to promote constant improvement in cell therapies, and such comparisons will likely show that individually tailored cells can address disease-specific clinical needs. The principle underlying such an approach is resistance to the notion that comprehensive characterization of any cell type has been achieved, neither in terms of phenotype nor risks-to-benefits ratio. Tailoring cell therapy approaches to specific conditions also requires an understanding of basic disease mechanisms and close collaboration between translational researchers and clinicians, to identify current needs and shortcomings in existing treatments. To this end, the international workshop entitled {"}Placenta-derived stem cells for treatment of inflammatory diseases: moving toward clinical application{"} was held in Brescia, Italy, in March 2009, and aimed to harness an understanding of basic inflammatory mechanisms inherent in human diseases with updated findings regarding biological and therapeutic properties of human placenta-derived cells, with particular emphasis on their potential for treating inflammatory diseases. Finally, steps required to allow their future clinical application according to regulatory aspects including good manufacturing practice (GMP) were also considered. In September 2009, the International Placenta Stem Cell Society (IPLASS) was founded to help strengthen the research network in this field.",
author = "Ornella Parolini and Francesco Alviano and Irene Bergwerf and Diana Boraschi and {De Bari}, Cosimo and {De Waele}, Peter and Massimo Dominici and Marco Evangelista and Werner Falk and Simone Hennerbichler and Hess, {David C} and Giacomo Lanzoni and Bing Liu and Fabio Marongiu and Colin McGuckin and Stefan Mohr and Nolli, {Maria Luisa} and Racheli Ofir and Peter Ponsaerts and Luca Romagnoli and Abraham Solomon and Maddalena Soncini and Stephen Strom and Daniel Surbek and Sankar Venkatachalam and Susanne Wolbank and Steffen Zeisberger and Andy Zeitlin and Andreas Zisch and Borlongan, {Cesar V.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1089/scd.2009.0404",
language = "English (US)",
volume = "19",
pages = "143--154",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Toward cell therapy using placenta-derived cells

T2 - Disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table

AU - Parolini, Ornella

AU - Alviano, Francesco

AU - Bergwerf, Irene

AU - Boraschi, Diana

AU - De Bari, Cosimo

AU - De Waele, Peter

AU - Dominici, Massimo

AU - Evangelista, Marco

AU - Falk, Werner

AU - Hennerbichler, Simone

AU - Hess, David C

AU - Lanzoni, Giacomo

AU - Liu, Bing

AU - Marongiu, Fabio

AU - McGuckin, Colin

AU - Mohr, Stefan

AU - Nolli, Maria Luisa

AU - Ofir, Racheli

AU - Ponsaerts, Peter

AU - Romagnoli, Luca

AU - Solomon, Abraham

AU - Soncini, Maddalena

AU - Strom, Stephen

AU - Surbek, Daniel

AU - Venkatachalam, Sankar

AU - Wolbank, Susanne

AU - Zeisberger, Steffen

AU - Zeitlin, Andy

AU - Zisch, Andreas

AU - Borlongan, Cesar V.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Among the many cell types that may prove useful to regenerative medicine, mounting evidence suggests that human term placenta-derived cells will join the list of significant contributors. In making new cell therapy-based strategies a clinical reality, it is fundamental that no a priori claims are made regarding which cell source is preferable for a particular therapeutic application. Rather, ongoing comparisons of the potentiality and characteristics of cells from different sources should be made to promote constant improvement in cell therapies, and such comparisons will likely show that individually tailored cells can address disease-specific clinical needs. The principle underlying such an approach is resistance to the notion that comprehensive characterization of any cell type has been achieved, neither in terms of phenotype nor risks-to-benefits ratio. Tailoring cell therapy approaches to specific conditions also requires an understanding of basic disease mechanisms and close collaboration between translational researchers and clinicians, to identify current needs and shortcomings in existing treatments. To this end, the international workshop entitled "Placenta-derived stem cells for treatment of inflammatory diseases: moving toward clinical application" was held in Brescia, Italy, in March 2009, and aimed to harness an understanding of basic inflammatory mechanisms inherent in human diseases with updated findings regarding biological and therapeutic properties of human placenta-derived cells, with particular emphasis on their potential for treating inflammatory diseases. Finally, steps required to allow their future clinical application according to regulatory aspects including good manufacturing practice (GMP) were also considered. In September 2009, the International Placenta Stem Cell Society (IPLASS) was founded to help strengthen the research network in this field.

AB - Among the many cell types that may prove useful to regenerative medicine, mounting evidence suggests that human term placenta-derived cells will join the list of significant contributors. In making new cell therapy-based strategies a clinical reality, it is fundamental that no a priori claims are made regarding which cell source is preferable for a particular therapeutic application. Rather, ongoing comparisons of the potentiality and characteristics of cells from different sources should be made to promote constant improvement in cell therapies, and such comparisons will likely show that individually tailored cells can address disease-specific clinical needs. The principle underlying such an approach is resistance to the notion that comprehensive characterization of any cell type has been achieved, neither in terms of phenotype nor risks-to-benefits ratio. Tailoring cell therapy approaches to specific conditions also requires an understanding of basic disease mechanisms and close collaboration between translational researchers and clinicians, to identify current needs and shortcomings in existing treatments. To this end, the international workshop entitled "Placenta-derived stem cells for treatment of inflammatory diseases: moving toward clinical application" was held in Brescia, Italy, in March 2009, and aimed to harness an understanding of basic inflammatory mechanisms inherent in human diseases with updated findings regarding biological and therapeutic properties of human placenta-derived cells, with particular emphasis on their potential for treating inflammatory diseases. Finally, steps required to allow their future clinical application according to regulatory aspects including good manufacturing practice (GMP) were also considered. In September 2009, the International Placenta Stem Cell Society (IPLASS) was founded to help strengthen the research network in this field.

UR - http://www.scopus.com/inward/record.url?scp=77649171426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649171426&partnerID=8YFLogxK

U2 - 10.1089/scd.2009.0404

DO - 10.1089/scd.2009.0404

M3 - Review article

C2 - 19947828

AN - SCOPUS:77649171426

VL - 19

SP - 143

EP - 154

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 2

ER -